Search results for "Random"

showing 10 items of 3931 documents

Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group.

1997

Ethanol injection has been reported to be effective in the treatment of hepatocellular carcinoma, but no controlled randomized trials have been performed. We therefore performed a trial comparing ethanol injection with an untreated, matched historical comparison group in the treatment of hepatocellular carcinoma.From 1992 to 1993, 35 patients (14 Child's A and 21 Child's B cirrhosis) with small (4 cm) hepatocellular carcinoma associated with cirrhosis were treated by ethanol injection. Each patient was matched with an untreated case (followed up during the period 1984-89) for variables known to have independent prognostic value (age, Child's classification, number of lesions, alpha-fetoprot…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentEthanol InjectionGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemotherapyEthanolbusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseConfidence intervalSurvival RateHepatocellular carcinomaCase-Control StudiesSolventsFemalePercutaneous ethanol injectionComplicationbusinessScandinavian journal of gastroenterology
researchProduct

TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials

1999

To compare the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation with those of endoscopic treatment with or without propranolol administration (i.e, conventional treatment) on recurrent bleeding, encephalopathy, and mortality by using meta-analysis of 11 published randomized clinical trials.Data from 11 relevant studies were retrieved by means of computerized and manual search. The combinability of the studies was assessed in terms of clinical and statistical criteria. Data were extracted on the basis of the intention-to-treat principle, and treatment effects were measured as risk differences between TIPS creation and conventional treatment. Pooled estimates were comp…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentEncephalopathyEsophageal and Gastric Variceslaw.inventionRandomized controlled trialRecurrenceRisk FactorslawSclerotherapymedicineSclerotherapyHumansRadiology Nuclear Medicine and imagingbusiness.industryLiver DiseasesHemostasis EndoscopicMiddle Agedmedicine.diseaseSurgeryHepatic EncephalopathyMeta-analysisPortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageVaricesbusinessTransjugular intrahepatic portosystemic shuntRadiology
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

2022

Background: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investigational drugs for NASH on validated histological outcomes.Data synthesis: A comprehensive search was conducted to detect phase 2 and 3 RCTs comparing pharmacological interventions in patients with NASH. According to Food and Drug Administra-tion (FDA) recommendations, primary outcomes included: 1) NASH resolution without wors-ening of fibrosis; 2) At least 1-point reduction in fibrosis without worsening of NASH. Meta -analysis and meta-regression…

Liver CirrhosisNutrition and DieteticsLiverNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismNetwork Meta-AnalysisMeta-analysis NASH Network meta-analysisMedicine (miscellaneous)HumansVitamin EDrugs InvestigationalCardiology and Cardiovascular MedicineRandomized Controlled Trials as Topic
researchProduct

Treatment of hepatitis C: critical appraisal of the evidence

2005

Chronic hepatitis C virus infection is currently the most common cause of end stage liver disease worldwide. Although the conclusions of the last National Institutes of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues remain unanswered. This paper reviews the available data using an evidence-based approach. Current evidence is sufficient to recommend IFN treatment for all patients with acute hepatitis. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1 is the best treatment option. The current gold standard of efficacy for treatment-naive patients with ch…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularCirrhosisInterferon alpha-2Antiviral AgentsPolyethylene Glycolschemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicinemedicineHumansPharmacology (medical)Randomized Controlled Trials as TopicPharmacologybusiness.industrycombination treatment hepatitis C histological benefit meta-analysis pegylated interferonRibavirinLiver NeoplasmsInterferon-alphaGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CRecombinant ProteinschemistryTolerabilityHepatocellular carcinomaMeta-analysisAcute DiseaseImmunologybusinessmedicine.drug
researchProduct

Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment.

1992

We updated meta-analysis and critical descriptive analysis of randomized clinical trials (RCTs) assessing the value of beta-blockers in preventing first bleeding (prophylactic) or rebleeding (therapeutic) and on survival of patients with cirrhosis. Both the methods of Peto-Mantel-Haenszel and DerSimonian-Laird were used to assess the heterogeneity and obtain cumulative estimates of treatment effects; the L'Abbé plot was also used for a visual assessment of heterogeneity in the direction of treatment effect. Seven prophylactic and nine therapeutic RCTs were analysed. beta-Blockers uniformly reduced the bleeding risk and revealed a trend toward improved survival in non-ascitic, well-compensat…

Liver Cirrhosismedicine.medical_specialtyCirrhosisAdrenergic beta-AntagonistsEsophageal and Gastric Variceslaw.inventionRandomized controlled triallawRecurrenceHypertension PortalMedicineHumansIntensive care medicineMedical treatmentbusiness.industryIncidenceGastroenterologyHemodynamicsGeneral Medicinemedicine.diseaseSurgeryMeta-analysisPortal hypertensionUpper gastrointestinal bleedingbusinessGastrointestinal HemorrhageDigestive diseases (Basel, Switzerland)
researchProduct

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized contr…

2009

Radiofrequency thermal ablation (RF) and percutaneous ethanol injection (PEI) have been employed in the treatment of small hepatocellular carcinoma (HCC) as curative treatments. The aim of the study was to review the available evidence comparing RF to PEI for small HCC.Cochrane, MEDLINE, CANCERLIT, and ENBASE databases were used.randomized clinical trials evaluating RF vs. PEI. Data were extracted from each randomized controlled trial (RCT). Primary outcomes were overall survival and local recurrence. Meta-analysis software was used and risk differences (RDs) and their 95% confidence intervals and Q-test for heterogeneity were calculated.Five RCTs were identified including 701 patients. The…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentThermal ablationUrologyCatheter ablationInjections Intralesionallaw.inventionRandomized controlled triallawmedicineHumansSurvival rateRandomized Controlled Trials as TopicHepatologyEthanolbusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseSurgerySurvival RateTreatment OutcomeMeta-analysisHepatocellular carcinomaCatheter AblationSolventsPercutaneous ethanol injectionbusinessThe American journal of gastroenterology
researchProduct

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update.

2020

Background: Lifestyle interventions aimed at weight loss have been associated with improved liver enzymes, reduced intrahepatic triglyceride content, and improved histology (including reduced fibrosis stage). Objective: To revise the evidence on the beneficial effects of lifestyle changes accumulated since 2015, following the publication of the pivotal Cuban experience with histologic outcome. Methods: A PubMed search covering the period 2015 to July 2019 was carried out. All retrieved references were analyzed and double-checked by authors. Results: 20 new studies were identified; in addition, two relevant studies provided new evidence. Thirteen studies were classified as randomized, contr…

Liver Cirrhosismedicine.medical_specialtyFibrosiLiver CirrhosiPopulationMotivational interviewingInformation technology01 natural sciencesTriglycerideElectronic mail03 medical and health sciencesWeight lossFood intakeNon-alcoholic Fatty Liver DiseaseDrug DiscoveryNonalcoholic fatty liver diseaseWeight LossmedicineHumanseducationLife StyleTriglycerides030304 developmental biologyRandomized Controlled Trials as TopicPharmacology0303 health scienceseducation.field_of_studyInternetText MessagingCirrhosiElectronic Mailbusiness.industrymedicine.diseasePhysical activity steatosiWeight Lo0104 chemical sciencesTelephone010404 medicinal & biomolecular chemistryObservational Studies as TopicBehavior therapyCohortPhysical therapyObservational Studies as TopicObservational studymedicine.symptomBehavior therapy Cirrhosis Fibrosis Food intake Information technology Physical activity steatosisbusinessHumanCurrent pharmaceutical design
researchProduct

Volume and effectiveness assessment of articain 4% versus mepivacaine 2% used in third molar surgery : randomized, double-blind, split-mouth controll…

2020

Made available in DSpace on 2021-06-25T11:06:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-01-01 Background: The different indications for extraction of the lower third molars, require resources to manage pain and discomfort, such as, for example, adequate anesthetic techniques, and the type of anesthetic used can in-fluence the management of pain in tooth extractions. Few studies in the literature compare the anesthetics 4% articaine hydrochloride and 2% mepivacaine hydrochloride showing evidence that both allow for successful pain management. This study sought to compare the volume, efficacy and safety of these two anesthetic drugs, both associated with epinephrine at a ratio …

Local anaesthesiaVisual analogue scaleAnesthesia DentalMepivacainePainCarticaineArticaineArticaine Hydrochloridelaw.inventionCarticaineRandomized controlled trialDouble-Blind MethodlawThird molarmedicineHumansParesthesiaAnesthetics LocalGeneral Dentistrybusiness.industryResearch:CIENCIAS MÉDICAS [UNESCO]Clinical trialOtorhinolaryngologyAnesthesiaAnestheticMepivacaineTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryMolar ThirdOral Surgerybusinessmedicine.drug
researchProduct